AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Guanylyl cyclase C

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P25092

UPID:

GUC2C_HUMAN

Alternative names:

Heat-stable enterotoxin receptor; Intestinal guanylate cyclase

Alternative UPACC:

P25092; B2RMY6

Background:

Guanylyl cyclase C, also known as the heat-stable enterotoxin receptor or intestinal guanylate cyclase, plays a pivotal role in the synthesis of cyclic GMP (cGMP) from GTP. This enzyme is uniquely activated by bacterial enterotoxins, such as those from E.coli, and endogenous peptides like guanylin and uroguanylin, highlighting its critical function in gastrointestinal physiology.

Therapeutic significance:

The association of Guanylyl cyclase C with diseases such as Diarrhea 6 and Meconium ileus, conditions stemming from gene variants affecting this protein, underscores its therapeutic potential. Targeting this enzyme could lead to innovative treatments for these gastrointestinal disorders, offering hope for patients suffering from these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.